Cognitive impairments in autoimmune encephalitis: the role of autoimmune antibodies and oligoclonal bands.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 28 03 2024
accepted: 03 09 2024
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: epublish

Résumé

The presence of oligoclonal bands (OCBs) in cerebrospinal fluid (CSF) is a pivotal diagnostic marker for multiple sclerosis (MS). These bands play a crucial role in the diagnosis and understanding of a wide array of immune diseases. In this study, we explore the relationship between the cognitive profile of autoimmune encephalitis (AIE) and the presence of OCBs in CSF, with a particular emphasis on NMDA receptor antibodies. We studied a cohort of 21 patients across five tertiary centers, segregated into two distinct categories. One group comprised individuals who tested positive only for autoimmune encephalitis antibodies indicative of encephalitis, while the other group included patients whose CSF was positive for both autoimmune encephalitis antibodies and OCBs. Our investigation focused primarily on cognitive functions and behavioral alterations, supplemented by auxiliary diagnostic assessments such as CSF cell count, magnetic resonance imaging (MRI), and electroencephalogram (EEG) results, evaluated for the two patient groups. To validate our findings, we employed statistical analyses such as Fisher's exact test with Benjamini-Hochberg correction. Our study included 21 patients, comprising 14 who were presented with only autoimmune encephalitis antibodies, and 7 who were dual-positive. Among these patients, we focused on those with NMDA receptor antibodies. Of these, five were dual positive, and nine were positive only for NMDA receptor antibodies. The dual-positive NMDA group, with an average age of 27 ± 16.47 years, exhibited significantly higher CSF cell counts (p=0.0487) and more pronounced language and attention deficits (p= 0.0264). MRI and EEG results did not differ significantly between the groups. Our results point to OCBs as an additional marker of disease severity in AIE, especially in NMDA receptor-antibody positive patients, possibly indicating a broader inflammatory process, as reflected in elevated CSF lymphocytes. Regular testing for OCBs in cases of suspected AIE may aid in disease prognosis and identification of patients more prone to language and attention disorders, improving diagnosis and targeting treatment for these cognitive aspects.

Identifiants

pubmed: 39403380
doi: 10.3389/fimmu.2024.1405337
pmc: PMC11472350
doi:

Substances chimiques

Oligoclonal Bands 0
Autoantibodies 0
Receptors, N-Methyl-D-Aspartate 0
Biomarkers 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1405337

Informations de copyright

Copyright © 2024 Rozenberg, Shelly, Vaknin-Dembinsky, Friedman-Korn, Benoliel-Berman, Spector, Yarovinsky, Guber, Gutter Kapon, Wexler and Ganelin-Cohen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Ayal Rozenberg (A)

Department of Neurology, Rambam Health Care Campus, Haifa, Israel.
Neuroimmunology Laboratory, Ruth and Bruce Rapaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Shahar Shelly (S)

Department of Neurology, Rambam Health Care Campus, Haifa, Israel.
Neuroimmunology Laboratory, Ruth and Bruce Rapaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Adi Vaknin-Dembinsky (A)

Department of Neurology and Laboratory of Neuroimmunology and Agnes-Ginges Center for Neurogenetics, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Tal Friedman-Korn (T)

Department of Neurology and Laboratory of Neuroimmunology and Agnes-Ginges Center for Neurogenetics, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Tal Benoliel-Berman (T)

Department of Neurology and Laboratory of Neuroimmunology and Agnes-Ginges Center for Neurogenetics, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Polina Spector (P)

Department of Neurology, Carmel Medical Center, Haifa, Israel.

Natalya Yarovinsky (N)

Department of Neurology, Rambam Health Care Campus, Haifa, Israel.

Diana Guber (D)

Multiple Sclerosis Center, Sheba Medical Center, Tel Hashomer, Israel.
Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Lilach Gutter Kapon (L)

Clinical Immunology and Tissue Typing Laboratory, Rambam Health Care Campus, Haifa, Israel.

Yair Wexler (Y)

School of Neurobiology, Biochemistry and Biophysics, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

Esther Ganelin-Cohen (E)

Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Neuroimmunological Clinic, Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH